Jeeyun Lee
Clinical trials sponsored by Jeeyun Lee, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for hard-to-treat stomach cancer? drug duo targets MET gene Results expected Dec 2026 (estimated)
-
New hope for Hard-to-Treat stomach cancer: drug cocktail trial launches
Disease control Recruiting nowThis phase II trial is testing a combination of three drugs—trastuzumab deruxtecan, capecitabine, and rilvegostomig—in people with HER2-positive, locally advanced stomach cancer that cannot be removed by surgery right away. The goal is to see if giving these drugs before and afte…
Phase 2 • Sponsor: Jeeyun Lee • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for hard-to-treat stomach cancer? drug duo targets MET gene
Disease control Recruiting nowThis study tests a combination of two drugs, savolitinib and durvalumab, in people with advanced stomach cancer that has a specific gene change called MET amplification. Participants must have already tried at least one chemotherapy that didn't work. The goal is to see if this co…
Phase 2 • Sponsor: Jeeyun Lee • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy offers hope for hard-to-treat stomach cancer
Disease control Recruiting nowThis study is for people with advanced HER2-low stomach cancer that has not responded to earlier treatments. It tests a combination of two targeted drugs, trastuzumab deruxtecan (T-DXd) and afatinib, to see if they work better together. The goal is to shrink tumors and improve su…
Phase 1/2 • Sponsor: Jeeyun Lee • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC